Built around measurable decisions
Abbott's public history begins in Chicago in 1888. This site translates that long operating context into a practical review framework for diagnostic, monitoring, and infection-control buyers.
Evaluation horizon
These gates describe how a hospital can evaluate innovation; they are not release dates or regulatory claims for a specific Abbott product.
Define clinical question, population, care setting, comparator, and measurable acceptance threshold.
Review analytical or clinical performance, confidence intervals, clinical evaluation report (CER), risk-benefit analysis, limitations, and intended-use alignment.
Test HL7/FHIR messages, identity, timestamps, security controls, downtime, and reconciliation.
Run a controlled cohort with versioned protocol, trained operators, predefined deviations, and go/no-go criteria.
Track drift, complaints, field actions, software changes, consumables, post-market surveillance (PMS), and adverse event reporting (MDR).
Context, not nostalgia
Abbott's documented company story begins with Dr. Wallace C. Abbott's Chicago practice.
ISO 13485:2016 formalized risk-based quality-system expectations now central to supplier review.
EU IVDR 2017/746 reframed evidence and lifecycle obligations for in-vitro diagnostics.
FDA cybersecurity expectations made secure product development and update planning procurement issues.
Clinical teams increasingly evaluate devices, data pathways, service, and consumables as one operating system.
Interoperability ecosystem
These are standards and stakeholder systems, not partnership endorsements.
Co-development starts with constraints
Describe the current workflow, failure mode, intended users, data destination, and evidence required for a decision.
Use the Innovation Lab framework